Celgene hands PD-1 med back to BeiGene, forfeiting $150M by Amirah Al Idrus Monday, June 17, 2019 Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.
BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics by Nick Paul Taylor Tuesday, November 27, 2018 The agreement gives Zymeworks $40 million upfront, a potential ongoing income stream and a global development partner.
SpringWorks names a CEO, inks a combo therapy deal with BeiGene by Amirah Al Idrus Thursday, September 6, 2018 SpringWorks Therapeutics named its first CEO and unveiled a partnership with BeiGene around a combination therapy for RAS-mutated cancers.
Shkreli in the stocks; still sharing biotech tips by Amirah Al Idrus Tuesday, July 3, 2018 Martin Shkreli, infamous for his combative tweets and general "insolent" demeanor, may be blogging biopharma tips from prison.
BeiGene to use Medidata’s ePRO solution for oncology studies by Angus Liu Wednesday, July 26, 2017 BeiGene is adding Medidata’s electronic patient-reported outcome solution to oncology clinical studies.
Celgene bags Beigene PD-1 drug for $263M up front by Nick Paul Taylor Thursday, July 6, 2017 Celgene has bought itself a spot toward the back of the pack in the PD-1 inhibitor market.
